MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$37,236K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Share-based compensation
Accounts payable and accrued lia...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-42,286
-35,352
-35,216
-101,844
Depreciation and amortization
153
151
157
160
Operating lease right-of-use and fixed asset impairment
-
-
4,136
-
Noncash consideration portion of zentera in-process research and development
-
-
0
-
Fixed asset impairment
0
-1,152
-
0
Share-based compensation
3,215
3,197
3,122
4,828
Goodwill impairment
-
-
0
-
Gain on disposal of equipment
0
-
26
103
Non-cash impact of revenues from licensing and sales of intellectual property
-
-
0
0
Non-cash recognized loss on mark-to-market of equity securities
0
0
152
3,470
Accretion of discounts on marketable securities, net
49
224
431
517
Loss on equity method investment
-
-
0
-
Deferred income taxes
-
-
0
-
Deconsolidation of kalyra
-
-
0
0
Accounts receivable
-
-
-5,000
-
Contracts receivable
0
5,000
-
0
Prepaid expenses and other assets
367
-973
698
-679
Accounts payable and accrued liabilities
2,259
-1,451
-733
-1,976
Operating lease right-of-use assets and liabilities, net
-161
-250
53
127
Net cash used in operating activities
-37,236
-32,956
-30,940
-26,963
Purchases of marketable securities
29,976
29,952
30,238
49,534
Proceeds from maturities of marketable securities
60,000
60,000
60,000
60,000
Proceeds from sale of marketable equity securities
-
-
2,558
17,855
Proceeds from sale of property and equipment
0
0
129
0
Purchases of property and equipment
0
34
0
0
Net cash provided by investing activities
30,024
30,014
32,449
28,321
Proceeds from issuance of common stock, net
-
-
5,390
-
Proceeds from issuance of common stock under equity incentive plans
65
331
0
115
Repurchase of common stock
-
-
9,976
-
Net-settlement of restricted stock unit vesting
0
1,454
0
0
Net cash (used in) provided by financing activities
65
-1,123
-4,586
115
Net (decrease) increase in cash, cash equivalents and restricted cash
-7,147
-4,065
-3,077
1,473
Cash, cash equivalents and restricted cash at beginning of period
34,557
38,622
41,699
36,528
Cash, cash equivalents and restricted cash at end of period
27,410
-
-
-
Cash and cash equivalents
24,783
-
-
-
Restricted cash
2,627
-
-
-
Total cash, cash equivalents and restricted cash reported in the condensed consolidated statements of cash flows
27,410
34,557
38,622
41,699
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$60,000K
(-53.85%↓ Y/Y)
Proceeds from issuance of
common stock under...
$65K
(-65.61%↓ Y/Y)
Net cash provided by
investing activities
$30,024K
(-57.62%↓ Y/Y)
Net cash (used in)
provided by financing...
$65K
(-65.61%↓ Y/Y)
Canceled cashflow
$29,976K
Net (decrease)
increase in cash, cash...
-$7,147K
(-293.27%↓ Y/Y)
Canceled cashflow
$30,089K
Share-based compensation
$3,215K
(-74.83%↓ Y/Y)
Accounts payable and
accrued liabilities
$2,259K
(115.47%↑ Y/Y)
Depreciation and
amortization
$153K
(-63.74%↓ Y/Y)
Purchases of marketable
securities
$29,976K
(-49.80%↓ Y/Y)
Net cash used in
operating activities
-$37,236K
(44.71%↑ Y/Y)
Canceled cashflow
$5,627K
Net loss
-$42,286K
Prepaid expenses and
other assets
$367K
(112.18%↑ Y/Y)
Operating lease
right-of-use assets and...
-$161K
(-866.67%↓ Y/Y)
Accretion of discounts on
marketable securities, net
$49K
(-97.30%↓ Y/Y)
Buy us a coffee
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)